Clinical Trial Update: A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing amivantamab plus lazertinib versus osimertinib in locally advanced or metastatic non-small cell lung cancer is active/not recruiting wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Lazertinib (lazertinib)
• Osimertinib (osimertinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-09